BioCorRx Inc. reported substantial business developments in the first quarter of 2025, highlighting strategic moves that position the company for potential expansion in the substance use disorder treatment market. The pharmaceutical company completed a significant asset acquisition of LUCEMYRA® (lofexidine), an FDA-approved prescription medication designed to mitigate opioid withdrawal symptoms. This acquisition has already demonstrated financial impact, with net product revenues from LUCEMYRA rising from $3,620 in the first quarter of 2024 to $134,899 in the same period of 2025, representing a substantial increase that underscores the potential of the newly acquired medication.
CEO Lourdes Felix emphasized the company's commitment to managing operational costs, noting a reduction in operating expenses by approximately 9% compared to the previous year. The strategic acquisition of LUCEMYRA is expected to be a key revenue driver and potentially enhance shareholder value. LUCEMYRA itself represents an innovative approach to opioid withdrawal management as the first and only non-opioid medication FDA-approved to mitigate withdrawal symptoms, offering a targeted treatment option for patients undergoing opioid detoxification. The medication works by reducing norepinephrine release, thereby suppressing the neurochemical surge associated with withdrawal.
Concurrently, BioCorRx Pharmaceuticals continues developing sustained-release naltrexone products, supported by a significant grant from the National Institutes of Health's National Institute on Drug Abuse. The grant focuses on BICX104, a subcutaneous implantable pellet targeting methamphetamine use disorder (MUD), a significant public health challenge. This research is particularly important given the lack of approved medications for MUD and the expanding demographic at risk of methamphetamine-related overdose deaths. With more than 16.6 million people having used methamphetamine at least once in their lifetime, according to the 2022 National Survey on Drug Use and Health, the development of BICX104 could represent a critical intervention.
The company's comprehensive approach to substance use disorders extends beyond pharmaceutical interventions. Their Beat Addiction Recovery program integrates proprietary Cognitive Behavioral Therapy modules with peer support and medication-assisted treatments, demonstrating a holistic approach to addressing complex health challenges. As the global healthcare landscape continues to evolve, BioCorRx's strategic acquisitions and ongoing research represent a promising direction in developing comprehensive solutions for substance use disorders.
